NCT00818064View on ClinicalTrials.gov

Safety and Tolerability of Anti-IL-20 in Healthy Volunteers and Patients With Rheumatoid Arthritis

PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

InflammationRheumatoid ArthritisHealthy

Interventions

DRUG

anti-IL-20

Single s.c. injection (per dose cohort)

DRUG

placebo

Single s.c. injection (per dose cohort)

Trial Locations (1)

9728 NZ

Novo Nordisk Investigational Site, Groningen

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY